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The phagocyte–microbe interactions in the immune system is a defense mechanism but
when excessively or inappropriately deployed can harm host tissues and participate in
the development of different non-immune and immune chronic inflammatory diseases
such as autoimmune problems, allergies, some rheumatoid disorders, cancers and
others. Immunodrugs include organic synthetics, biological agents such as cytokines
and antibodies acting on single targets or pathways have been used to treat
immune-related diseases but with limited success. Most of immunostimulants and
immunosuppressants in clinical use are the cytotoxic drugs which possess serious
side effects. There is a growing interest to use herbal medicines as multi-component
agents to modulate the complex immune system in the prevention of infections rather
than treating the immune-related diseases. Many therapeutic effects of plant extracts
have been suggested to be due to their wide array of immunomodulatory effects
and influence on the immune system of the human body. Phytochemicals such as
flavonoids, polysaccharides, lactones, alkaloids, diterpenoids and glycosides, present in
several plants, have been reported to be responsible for the plants immunomodulating
properties. Thus the search for natural products of plant origin as new leads for
development of potent and safe immunosuppressant and immunostimulant agents is
gaining much major research interest. The present review will give an overview of
widely investigated plant-derived compounds (curcumin, resveratrol, epigallocatechol-
3-gallate, quercetin, colchicine, capsaicin, andrographolide, and genistein) which have
exhibited potent effects on cellular and humoral immune functions in pre-clinical
investigations and will highlight their clinical potential.
Keywords: immunomodulation, curcumin, resveratrol, epigallocatechol-3-gallate, quercetin, colchicine,
capsaicin
Introduction
Immunity is the body’s natural defense system against various infectious diseases. The factors which
trigger immunity include previous infection, immunization, and various external stimuli (Baxter,
2007). Besides, immunity is capable of discriminating among body’s own proteins/cells and foreign
entities. As soon as the foreign particle is identiﬁed, the collective and coordinated response of
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speciﬁc cells andmediators against strange substances constitutes
the immune response (Baxter, 2007). Based on the function,
immune system has been categorized in two broad categories,
i.e., innate immune system (non-speciﬁc immune system) and
adaptive immune system (speciﬁc or acquired immune system;
Vesely et al., 2011). The microbiological, chemical and physical
barriers are also sometimes included in innate immunity,
however, the main mediators of immune system which
deliver instant defense include cytokines, acute phase proteins,
macrophages, monocytes, complement, and neutrophils. Various
distinct moieties expressed by pathogens, known as pathogen-
associated molecular patterns (PAMPs), are recognized by
host to detect presence of a pathogen. The germline-encoded
and evolutionarily conserved host sensors known as pattern
recognition receptors (PRRs) recognize the PAMPs. Once the
PRRs recognize the PAMPs, an array of immune responses are
quickly triggered via induction of diﬀerent type I interferons,
chemokines, and cytokines. An important role in host’s defense is
played by PRRs families such as DNA receptors (cytosolic sensors
for DNA), NOD-like receptors, RIG-I-like receptors and toll-like
receptors (Parkin and Cohen, 2001). All phases of non-speciﬁc
immunity include antigen-presenting cells and macrophages
which play pivotal roles in antibody-dependent cell-mediated
cytotoxicity, secretion of cytokines, nitric oxide (NO) production
and antigen presentation, processing and phagocytosis. Dendritic
cells are responsible for the activation of naïve and memory
B and naïve T cells. During various phases of dendritic cells’
diﬀerentiation, the eﬀectors of innate immunity including natural
killer (NK) cells are regulated, which govern speciﬁc and
natural immune responses by producing tumor necrosis factor-
α (TNF-α), interferon-γ (IFN-γ) and granulocyte–macrophage
colony-stimulating factor (GM-CSF; Moradali et al., 2007).
Complement system is the tertiary relevant component of innate
immunity. The complement system is the humoral immunity’s
main eﬀector among all the physiological systems of host
defense (Oh et al., 2000). C3a and C3b (complement system’s
components) are activated by C9, and amplify and mediate
immune response.
Adaptive immunity is acquired by generating pathogen
(antigen)-speciﬁc B and T lymphocytes through a gene
rearrangement process. The exposure of body to antigen with
aim to produce adaptive immune reaction that develops in
weeks/months but may last through whole life is called active
immunity. The active immunity may either be acquired or
natural. The immune system of higher animals is equipped
with adaptive immunity. The antigen speciﬁc reactions (via
B and T lymphoctyes) are involved in adaptive immunity.
The strong phagocytic action of myeloid cells and cytotoxic T
lymphocytes is enhanced by Th1 lymphocytes which produce
TNF-α, IFN-γ, and IL-2. The IL-4, IL-5, and IL-10 are produced
by Th2 lymphocytes (which are the mediators of humoral
immunity), categorized by B lymphocytes-mediated production
of antibodies. The toxins or microorganisms are neutralized
after binding with the antibodies. Moreover, antibodies have the
ability to opsonize diﬀerent pathogens, immobilize bacteria, and
trigger microorganisms’ destruction by phagocytes via activation
of complement proteins (Spellberg and Edwards, 2001). The cell
types involved in innate and adaptive immune responses are
summarized in Figure 1.
Immunomodulators
In healthy organism, the immune system maintains homeostasis
within the body. The function and eﬃciency of the
immune system are inﬂuenced by various exogenous and
endogenous factors resulting in either immunosuppression
or immunostimulation. Several agents possessing an activity
to normalize or modulate pathophysiological processes are
called immunomodulators (Puri et al., 1994). The biomolecules
of synthetic or biological origin capable of modulating,
suppressing and stimulating any components of adaptive
or innate immunity are known as immunomodulators,
immunorestoratives, immunoaugmentors, or biological
response modiﬁers. Immunomodulators are generally
categorized into immunoadjuvants, immunostimulants, and
immunosuppressants in clinical practice. Immunoadjuvants
are speciﬁc immune stimulators which enhance the eﬃcacy
of vaccine. Agents that activate or induce the mediators or
components of immune system are called as immunostimulants.
The resistance against autoimmunity, cancer, allergy, and
infection is enhanced by immunostimulants. On the other
hand, immunosuppressants are the molecules that inhibit the
immune system, can be used to control the pathological immune
reaction subsequent to organ transplantation. Additionally,
these agents can also be used in the treatment of infection-
associated immunopathology, hypersensitivity reactions, and
autoimmune diseases. A number of monoclonal antibodies
and chemically synthesized compounds are also being used
as immunomodulators. However, there are major limitations
to the general use of these agents which are summarized
in Table 1. Therefore, immunomodulatory entities with
additional safety and eﬀectiveness are still in need. Due to the
occurrence of chemical drugs-related adverse eﬀects, natural
immunomodulators are the potential agents to replace them in
therapeutic regimens.
Presently, majority of research and development still focuses
on biochemicals, biologics, or single compounds as lead
compounds that aim at particular targets linked with a
disease. It is diﬃcult to attain single compound chemicals
with high selectivity and potency, and low toxicity for targeted
molecular/cellular targets and diseases. Hence, the design and
development of drug candidates from numerous conventional
or complementary and alternative medicines is gaining interest.
The prevention and treatment of disease using plant-based
medicines has been reported in human history. In all cultures
and through all ages diﬀerent parts of a huge number of plants
were used as drugs against all kinds of ailments. Vinblastine,
vincristine and their semi-synthetic derivatives isolated from the
Madagascar periwinkle (Catharanthus roseus), capsaicin from
chili peppers (Capsicum species), paclitaxel from Paciﬁc yew
(Taxus brevifolia) and galantamine from the Caucasian snowdrop
(Galanthus caucasicus) are examples of medicines based on
plant compounds. The plant-based compounds that served as
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FIGURE 1 | Cells of innate and adaptive immune response.
lead structures and/or were chemically altered are dicoumarol
(warfarin), artemisinin (artemether), camptothecin (topotecan
and irinotecan), morphine (scores of derivatives), and salicylic
acid (acetylsalicylic acid; Oberlies and Kroll, 2004).
The immunomodulatory characteristics of plant-based
therapeutics have gathered attention of researchers. Innovative
technologies and the excessive research on immunomodulatory
natural products, plants, their extracts, and their active moieties
with immunomodulatory potential, may provide us with
valuable entities to develop as novel immunomodulatory
agents to supplement the present chemotherapies. This review
focuses on the plant-based immunomodulatory compounds
undergoing clinical trials. Additionally, the potential use as
immunomodulatory agents, modes of action and plant origin of
numerous important plant-based lead compounds has also been
comprehensively discussed (Figure 2). Beside these compounds,
other phytochemicals including essential oils, steroids,
terpenoids, phenolics, pigments, ﬂavonoids, and alkaloids,
etc. have exhibited worth mentioning immunomodulatory
eﬀect. Plant-derived compounds showing promising potential as
immunomodulatory agents are listed in Table 2.
Selected Immunomodulatory
Plant-Derived Single Chemical Entities in
Clinical Trials
Curcumin
Curcumin is a natural diarylheptanoid compound found
in the rhizome of Curcuma longa and related species. The
medicinal beneﬁts of curcumin have been known since centuries.
A variety of biological and pharmacological properties of
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FIGURE 2 | Chemical structures of selected plant-derived immunomodulators in clinical trials.
curcumin has been reported including anti-cancer, anti-
oxidant, anti-angiogenic, anti-proliferative, pro-apoptotic, etc.
Curcumin is one of the most extensively studied compound
for its immunomodulatory properties. Curcumin lessened
inﬂammatory responses by inhibiting NO production,
cyclooxygenase-2 (COX-2), nuclear factor-kappa B (NK-
kB), inducible nitric oxide synthase (iNOS), and lipoxygenase in
NK cells and IFN-γ, or TNF-α activated macrophages (Bhaumik
et al., 2000; Surh et al., 2001). In phorbol 12-myristate 13- acetate
(PMA) and H2O2-stimulated human myelomonoblastic cell
line, curcumin inhibited NF-κB activation via prevention of
degradation and phosphorylation of I kappa B alpha (IκB-α;
Singh and Aggarwal, 1995). Protein kinase C, which regulates
the proliferation and survival of cell, is activated by PMA.
Additionally, LPS and TNF-α also activate protein kinase C,
which then activates NF-κB (Holden et al., 2008). Therefore,
curcumin might weaken NF-kB activation by the inhibition of
protein kinase C. The anti-inﬂammatory activity of curcumin
was partially mediated by inhibiting activator protein (AP)-1
and transcription factor NF-κB. NF-κB and AP-1 act collectively
and may enhance tumor development. The treatment of glioma
cells with 25 μM curcumin reduced the binding of NF-κB
and AP-1 (Dhandapani et al., 2007). The AP-1 activation was
also suppressed by curcumin in TNF-activated bovine aortic
endothelial cells (Xu et al., 1997). The activated immune
cells release pro-inﬂammatory cytokines that play key role in
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TABLE 2 | Plant derived immunomodulatory agents.
Chemical class Plant source Mechanism Reference
Alkaloids
Berberine Coptis chinensis
Franch
Down-regulate T-helper cells cytokines [Th1 (TNF-α, IL-2), and Th2
(IL-4)] production.
Lin and Lin (2011)
Chelerythrine Chelidonium majus L. Inhibit PGE2 release by regulating cyclooxygenase-2 activity Niu et al. (2011)
Gelselegine Gelsemium elegans Inhibited T lymphocyte proliferation. Xu et al. (2012)
Pseudocoptisine Corydalis
turtschaninovii Besser
Suppressing the phosphorylation of ERK and p38 to inhibit NF-κB
activation, which resulted in reduction of pro-inflammatory mediators
level (iNOS, COX-2, TNF-α, and IL-6).
Yun et al. (2009)
Leonurine Leonurus japonicas
Houtt
Downregulate TNF-α, IL-6, iNOS, and COX-2 and upregulate IL-10 by
inhibiting the expression of toll like receptors and the activation of
NF-κB. Inhibit the ICAM-1, VCAM-1 activity.
Liu et al. (2012), Song et al.
(2015)
Piperine Piper longum Linn Reduce level of pro inflammatory cytokines IL-1β, IL-6, and TNF-α.
Down regulate expression of COX-2, NOS-2, and NF-κB.
Inhibit eicosanoide generation by inhibiting phospholipase A2 and TXA2
synthase activity.
Vaibhav et al. (2012), Son et al.
(2014)
Sinomenine Sinomenium acutum
(Thunb.) Rehd.etWils
Inhibit the production and release of inflammatory cytokine.
Inhibit expression of VCAM-1.
Chen et al. (2011), Oh et al.
(2012)
Koumine Gelsemium elegans Inhibit T lymphocyte proliferation. Xu et al. (2012)
Lycorine Lycoris radiate Inhibit iNOS and COX-2 activity. Kang et al. (2012)
Sophocarpine Sophora alopecuroides
L.
Inhibit production of NO and pro inflammatory cytokines TNF-α and
IL-6. Inhibit expression of iNOS and COX-2.
Zhang et al. (2008), Gao et al.
(2012)
Rhynchophylline Uncaria rhynchophylla
(Miq.) Jack
Inhibit phosphorylation of mitogen-activated protein kinases.
Inhibit production of pro inflammatory cytokines, NO, PGE2, monocyte
chemoattractant protein MCP-1, TNF-α, IL-1β.
Song et al. (2012)
Tetrandrine Stephania tetrandra Wu et al. (2011)
Matrine Sophora flavescens Ait Reduced production of reactive oxygen species inflammatory
mediators.
Inhibit myeloperoxidase and maleic dialdehyde activity.
Zhang et al. (2011)
Essential oils
Z-ligustilide Angelica sinensis (Oliv.)
Diels
Inhibit iNOS and COX-2 induction by regulating the NF-kB and MAPK
signal pathways.
Chung et al. (2012)
Tetramethylpyra-zine Ligusticum chuanxiong
Hort
Inhibit pro inflammatory cytokines and reactive oxygen species
production. Inhibit macrophages chemotaxis, neutrophile infiltration,
and nitric oxide synthase activity.
Block the phosphorylation of p38 mitogen-activated protein kinase.
Liu et al. (2010), Hu et al. (2013)
Flavonoids
Chalcone
Butein Semecarpus
anacardium, Dalbergia
odorifera,
Toxicodendron
vernicifluum
Suppress NO production by attenuating iNOS expression.
Inhibit translocation of NF-κB.
Wang et al. (2014)
Xanthohumol Humulus lupulus Inhibit NO production which is induced by LPS and INF-γ. Zhao et al. (2003)
Dihydroxanthohumol Humulus lupulus Inhibit NO production which is induced by LPS and INF-γ. Zhao et al. (2003)
Mallotophilippens C,
D, E
Mallotus, Philippinensis Inhibit mRNA gene expression of iNOS, COX-2, IL-6, and IL-1β.
Inactivate NF-κB.
Daikonya et al. (2004)
Licochalcone E Glycyrrhiza inflata Inhibit secretion of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α
by inhibiting the activity of NF-κB and activator protein (AP-1).
Lee et al. (2013a)
Flavones
Luteolin Lonicera
Japonica
Decreased secretion of inflammatory mediators (INF-γ, IL-6) reduced
COX-2, ICAM-1 expression.
Block heat shock protein 90 activity.
Chen et al. (2007, 2014), Ziyan
et al. (2007)
Apigenin Cynodon dactylon,
Salvia officinalis L.,
Portulaca oleracea,
Mentha longifolia
Downregulate expression of cytokines (IL-1α, TNF-α, IL-8).
Decreased response of Th1 and Th17 cells.
Downregulate the expression of COX-2 and iNOS.
Decreased expression of ICAM and VCAM leading to decreased
neutrophile Chemotaxis.
Nicholas et al. (2007), Kang
et al. (2009)
(Continued)
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TABLE 2 | Continued
Chemical class Plant source Mechanism Reference
Chrysin Picea crassifolia Inhibited production of pro-inflammatory cytokine (TNFα, IL-1β, and
IL-6).
By modulation of intracellular calcium reduce histamine release from
mast cells.
Hougee et al. (2005), Shin et al.
(2009), Bae et al. (2011)
Nobiletin Citrus nobilis Lour,
Citrus aurantium L.
Inhibit pro-inflammatory mediators, COX-2 and iNOS expression by
blocking NF-κB and MAPK signaling pathway.
Kang et al. (2011)
Baicalein Scutellaria altissima L. Inhibit mRNA expression of iNOS, COX-2, and TNF-α.
Inhibit production of NO and inflammatory cytokine (IL-1β, PGE2, and
TNF-α) by regulating NF-κB and ER-dependent pathway.
Inhibit adhesion and migration of leukocytes by inhibiting cell adhesion
molecules expression.
Chandrashekar et al. (2012),
Fan et al. (2013), Lee et al.
(2015)
Oroxylin A Scutellariae baicalensis
Georgi
Inhibit NO production and iNOS and COX-2 proteins expression of via
inhibiting nuclear factor-κB pathway.
Enhance antioxidant response element-luciferase reporter activity by
increasing the expression of nuclear factor erythroid 2-related factor 2
proteins.
Chen et al. (2000), Li et al.
(2007), Ye et al. (2014)
Wogonin Scutellaria baicalensis
Georgi
Inhibit adhesion and migration of leukocytes by inhibiting cell adhesion
molecules expression.
Reduces allergic airway inflammation by inducing eosinophil apoptosis
through activation of caspase-3.
Guo et al. (2007), Lee et al.
(2015), Lucas et al. (2015)
Flavonols
Quercetin Dysosma veitchii
Hemsl. et Wils
Decreased expression of pro-inflammatory cytokines, NF-κB, and iNOS.
Reduce expression of VCAM-1 and E-selectin.
Shaik et al. (2006), Kleemann
et al. (2011), Choi et al. (2012)
Kaempferol Found in various fruits
and vegetables
e.g., tea, tomato,
cruciferous vegetables,
apple, etc.
Reduce iNOS and COX-2 activity through suppression of the signaling
of STAT-1, NF-kappa B, and AP-1. Decrease the gene expression of
ICAM-1, VCAM-1, and monocyte chemotactic protein-1 (MCP-1).
Hamalainen et al. (2007), Kong
et al. (2013)
Rutin Ruta graveolens Inhibit leukocyte migration.
Suppress production of TNF-α and IL-6.
Inhibit activation of NF-κB and extracellular regulated kinases.
Yoo et al. (2014)
Flavanols
Epigallocatechin-3-
gallate
Camellia sinensis L. Inhibit reactive oxygen species generation, MAPKs phosphorylation,
adhesion molecules expression signal transducers and activators of
transcription 3 (STAT-3) and activating transcription factor 2
translocation through induction of heme oxygenase-1 and suppressors
of cytokine signaling -3 expression.
Lee et al. (2013b)
Isoflavones
Daidzein Pueraria mirifica,
Pueraria lobata, Glycine
max
Decreases TNF-α, IL-1β, MCP-1, NO, and iNOS expression at mRNA
level.
Hamalainen et al. (2007)
Genistein Glycine max Inhibited expression of iNOS and COX-2.
Decreased IL-1β and TNF-α production via activation of PPARs.
Valles et al. (2010)
Puerarin Pueraria lobata (wild)
Ohwi
Decrease cytokines level.
Inhibit NF-κB and activation of signal transducers and activators of
transcription 3 (STAT3).
Liu et al. (2013)
Phloroglucinols
Myrtucommulone Myrtus communis L. Inhibit the PGE2 production by inhibiting the mPGES-1 activity without
significantly inhibiting the COX enzymes activity.
Koeberle et al. (2009)
Arzanol Helichrysum italicum Reduce eicosanoids generation by inhibiting lipooxygenase and
cyclooxygenase activity in arachidonic acid metabolism pathway.
Rossi et al. (2009), Bauer et al.
(2011)
Quinones
Thymoquinone Nigella sativa L. Inhibited LPS-induced fibroblast proliferation and H2O2-induced
4-hydroxynonenal generation.
Inhibit IL-1β, TNF-α, MMP-13, COX-2, and PGE2 while blocking
phosphorylation of MAPK p38, ERK1/2, and NF-kBp65.
Vaillancourt et al. (2011)
Shikonin Lithospermum
erythrorhyzon Sieb.
etZucc.
Inhibit NF-κB activity, inhibit Th1 cytokines expression and induce Th2
cytokines.
Andújar et al. (2010)
(Continued)
Frontiers in Plant Science | www.frontiersin.org 7 August 2015 | Volume 6 | Article 655
Jantan et al. Natural immunomodulators with clinical potential
TABLE 2 | Continued
Chemical class Plant source Mechanism Reference
Emodin-8-O-β-D glucoside Polygonum
amplexicaule D. Don
var. sinense Forb.
Stimulate proliferation and differentiation of osteoblasts.
Inhibit PGE2 production by increased alkaline phosphatase expression
in MC3T3-E1.
Xiang et al. (2011)
Other
Apocynin Apocynum cannabinum
L. (Canadian hemp),
Picrorhiza kurroa Royle
ex Benth.
Inhibit NADPH oxidase activity.
Suppress pro-inflammatory cytokines and CD4+ and CD8+T cells
production.
Stefanska and Pawliczak
(2008), Kim et al. (2012)
Stilbenes
Resveratrol Fallopia japonica,
grape, nuts
Decrease MPO activity and mPGES-1 to basal levels.
Inhibit iNOS and COX-2 expression.
Reduce the pro-inflammatory cytokines IL-8, TNFα, IFN-γ, and IL-1α.
Increase the anti-inflammatory cytokine IL-10 level.
Youn et al. (2009), Vang et al.
(2011)
Piceatannol Fallopia japonica,
grape, nuts
Decrease iNOS expression.
Inhibit transcription factors activation such as NF-kB, ERK, and STAT3.
Youn et al. (2009), Vang et al.
(2011)
Terpenoid
14-deoxyandrographolide Andrographis
paniculata
Enhanced proliferation of lymphocytes.
Enhanced IL-2 induction in lymphocytes.
Kumar et al. (2004)
14-deoxy-11,12-
didehydroandrographolide
Andrographis
paniculata
Enhanced proliferation of lymphocytes.
Enhanced IL-2 induction in lymphocytes.
Kumar et al. (2004)
Ginsan Panax ginseng Enhances the production of cytokines and reactive oxygen species by
macrophages.
Stimulates the phagocytic activity of macrophages.
Shen et al. (2002), Song et al.
(2002)
Oleanolic acid Luffa cylindrica,
Phytolacca americana
Reduce level of IL-1α, IL-6, and TNF-α, as well as their effect on
complement pathway though the inhibition of C3 convertase.
Inhibits adenosine deaminase activity.
Brinker et al. (2007)
Echinocystic acid Luffa cylindrica Enhance phagocytic index of macrophages in humoral and
cell-mediated immune responses.
Khajuria et al. (2007)
Triptolide Tripterygium wilfordii Inhibits lymphocyte activation and pro-inflammatory cytokines gene
expression (IL-2, iNOS, TNF-α, COX-2, and IFN-γ).
It also inhibits activation of transcription factors such as NF-kB, NFAT,
and STAT3.
Brinker et al. (2007)
Demethylzelasteral Tripterygium wilfordii Inhibits proliferation of vascular endothelial cells. Ramgolam et al. (2000)
Celastrol Tripterygium wilfordii Inhibit expression of pro-inflammatory cytokines, adhesion molecules,
proteasome activity, and topoisomerase II.
Kannaiyan et al. (2011)
Asiaticoside Centella asiatica Decrease NO production. Hartog et al. (2009)
Madecassoside Centella asiatica Reduce spleen cells proliferation.
Inhibition of pro-inflammatory mediators such as TNF-α and IL-6.
Inhibit production of PGE2, and COX-2.
Li et al. (2009)
11-keto-β-boswellic acid Boswellia carteri Decrease pro-inflammatory cytokines such as IL-1, IL-2, IL-4, IL-6, and
IFN-γ through inhibition of NF-kB activation.
Ammon (2006)
inﬂammation. The expression of pro-inﬂammatory cytokines
TNF-α, IL-1, IL-6, and IL-12 was inhibited by curcumin via LPS-
or PMA-stimulatedmonocytes, macrophages, dendritic cells, and
splenic lymphocytes (Gao et al., 2004; Kim et al., 2005). The
attachment of T cells to endothelial and antigen presenting cells
is dependent on cell adhesion molecules. The attachment of
monocytes to endothelial cells was blocked by pre-treatment with
curcumin. Moreover, the expression of intracellular adhesion
molecule (ICAM)-1, vascular cell adhesion molecule (VCAM)-
1, and endothelial leukocyte adhesion molecule (ELAM)-1 was
also decreased in TNF-α-stimulated human umbilical vein
endothelial cells (HUVECs) via inhibition of NF-κB (Kumar
et al., 1998).
Jurenka (2009) reviewed pre-clinical and clinical trials of
curcumin that were carried out at diﬀerent places. Presently,
116 studies regarding the diverse actions of curcumin could
be found on http://www.clinicaltrials.gov/. Among these 99
studies were based on the anti-inﬂammatory properties of
curcumin. The most noticeable diseases for which trials had been
conducted were cancer (e.g., lung, prostate, breast, pancreatic,
and colorectal), rheumatoid arthritis and inﬂammatory bowel
diseases (IBD; ulcerative colitis and Crohn’s disease), which
reﬂect the pleiotropic actions of curcumin. This information
shows that curcumin is still under extensive clinical investigation.
Future clinical trials will predominantly deal with still ongoing
various types of cancer and the action of curcumin on cognitive
damage. Additionally, the inﬂammatory conditions will still be
studied. Curcumin often acts as an adjunct treatment or dietary
supplement to the standard therapy in these trials. The review on
eﬀects of curcumin in ulcerative colitis (Kumar et al., 2012) stated
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that curcumin, when given as adjunct therapy may be eﬀective
and safe therapy for the maintenance of remission in quiescent
ulcerative colitis. Nonetheless, more operationally thorough
randomized controlled trials are required. This conclusion from
the authors reﬂects the overall situation. The clinical trials are
frequently too weak and of low quality to draw a conclusion.
The main problem is the low number of enrolled patients, which
normally ranges from 10 to 30. It is worth mentioning that
curcumin suﬀers from its low bioavailability, though substantial
improvement has been made to address this issue via chemical
and technological methods (Anand et al., 2007). The future
of curcumin as an approved option for the prevention or
treatment of the above mentioned indications relies on the
ﬁndings of high-quality and big cohort studies in the future.
Still, from the available literature, a conclusion can be drawn
that curcumin exhibits good safety proﬁle; it is nontoxic and well
tolerated.
Resveratrol
Resveratrol, chemically (5-[(E)-2-(4-hydroxyphenyl) ethenyl]
benzene-1,3-diol), is a derivative of stilbene and phytoalexin.
It is found in various dietary products and plants including
grapevines, red wine and peanuts. Similar to curcumin,
resveratrol was found to exert a variety of pharmacological
activities such as antimicrobial, chemopreventive, anticancer/
proapoptotic, anti-inﬂammatory, and antioxidant properties.
The inﬂammatorymolecules are strongly inhibited by resveratrol.
The immunomodulatory activities of resveratrol include
the inhibition of NF-κB in PMA, LPS or TNF-α-mediated
macrophages, epithelial (HeLa), Jurkat, myeloid (U-937) and
dendritic cells. NF-κB activation was inhibited by resveratrol
via inhibition of IκB kinase (Holmes-McNary and Baldwin,
2000; Manna et al., 2000; Gao et al., 2001). The expression of
COX-2 and iNOS in cytokine (IFN, IL-1, or TNF-α) stimulated
human primary airway epithelial cells was also inhibited by
resveratrol (Donnelly et al., 2004) whereas it also blocked
the transcription of COX-2 in human mammary epithelial
cells stimulated by PMA. The secretion of NO and TNF-α in
LPS-activated N9 microglial and cortical microglia cells was
also substantially suppressed by resveratrol (Bi et al., 2005),
moreover the production of IL-12, IL-6, IL-1, TNF-α, and IFN-γ
and by splenic macrophages and lymphocytes was also inhibited
(Kowalski et al., 2005). Resveratrol also showed strong inhibition
of in vivo C5 anaphylatoxin (C5a)-mediated inﬂammation.
The release of inﬂammatory cytokines (MIP-1, IL-6, IL-1, and
TNF-α) in C5a-activated mouse and human neutrophils was
inhibited by the pre-incubation with resveratrol (10–40 M). In
addition, ERK-phosphorylation, release of glucuronide and C5a
induced oxidative burst (superoxide anion production) were
also inhibited by resveratrol. Furthermore, resveratrol inhibited
production of inﬂammatory cytokines and C5a-stimulated
neutrophil recruitment/migration in C5a-stimulated acute
peritonitis mouse model (Issuree et al., 2009). The expression
of cell adhesion molecules was also found to be inhibited
by resveratrol. The IL-6-stimulated ICAM-1 expression in
endothelial cells was also decreased by resveratrol (Wung et al.,
2005), in addition to the inhibition of Porphyromonas gingivalis
LPS-induced endothelial dysfunction in human microvascular
endothelial cells. Besides, ICAM-1 and VCAM-1 expression on
human microvascular endothelial cells was blocked by inhibition
of NF-κB activation (Park et al., 2009).
Based on the above-mentioned ﬁndings, a lot of emphasis was
put into the explanation of the underlying mechanisms of action.
Still, this enormous knowledge has yet not been translated into
anapproved clinical medicine. More than 40 clinical trials on
resveratrol have been listed in PubMed for a variety of diseases
like coronary artery disease, obesity, diabetes, and so forth. The
main focus of these studies was to either analyze inﬂammation-
related parameters in blood cells (e.g., transcription factors
or activated kinases) and in plasma (e.g., IL-6, IL-1β, TNF-
α) or to report on functional parameters like the status of
the endothelium (Bakker et al., 2010; Tome-Carneiro et al.,
2013). Several trials persuasively showed that these parameters
are usefully inﬂuenced by resveratrol. Though, whether this
improved inﬂammatory status of the patients indeed leads to a
clinically relevant improvement of the severity of the diseases
or, most signiﬁcantly, in a decreased incidence of disease-
speciﬁc life-threatening events has not been studied. Currently
99 studies are listed on http://www.clinicaltrials.gov/, 49 studies
have been completed while 28 clinical trials on resveratrol are
currently recruiting or planned. Among them 27 studies are
linked with the anti-inﬂammatory properties of resveratrol. The
main ﬁeld of interest is metabolic syndrome/type 2 diabetes,
followed by mild cognitive impairment, non-alcoholic fatty liver
disease, and polycystic ovary syndrome. Research would beneﬁt
by carrying out interventional studies with deﬁnite primary
outcomes reﬂecting the stage or/and occurrence of the diseases
on a long-term basis.
Epigallocatechin-3-gallate
One of the most active and abundant polyphenol of green
tea Camellia sinensis (Theaceae) is epigallocatechin-3-
gallate (EGCG), chemically [(2R,3R)-5,7-dihydroxy-2-(3,4,
5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl]3,4,5-trihy-
droxybenzoate]. It has been widely reported for its in vitro
and in vivo chemopreventive, anti-angiogenic, anti-invasive,
anti-proliferative, anti-inﬂammatory, and anti-oxidant eﬀects
(Singh et al., 2011; Yang et al., 2011b). Studies have showed
that EGCG blocked the activation of NF-κB by inhibiting the
degradation of IκBα (Muraoka et al., 2002) and also inhibited
the MAPK pathways (Chung et al., 2001). The down-regulation
of iNOS transcription and NO production in macrophages is
dependent on the inhibition of NF-κB. In comparison, it was
shown that EGCG improved the production of NO to inhibit
endothelial exocytosis and leukocyte adherence to endothelial
cells (Yamakuchi et al., 2008). Moreover, it was reported that
EGCG blocked NF-κB activation in human endothelial cells
and thus inhibited the expression of MCP-1 (Hong et al.,
2007). By reducing mRNA expression of bax and caspase3
and by decreasing caspase3 activity, EGCG also decreased
apoptosis (Hara et al., 2006; Park et al., 2006; Yu et al., 2007).
Additionally, it inhibited expression of COX-2, proteasome
dependent degradation, the MAPK pathway and growth factor-
dependent signaling (e.g., of IGF-I, VEGF, and EGF; Yang et al.,
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2011a). Likewise, EGCG inhibited DNA methyltransferase 1,
topoisomerase II and telomerase, thus aﬀecting the functions
of chromatin (Lee et al., 2005; Sadava et al., 2007; Bandele and
Osheroﬀ, 2008).
Surprisingly, though, notwithstanding encouraging pre-
clinical results and the detailed mechanistic insights, clinical
studies related to inﬂammation are lacking. A small scale study
investigated the action of green tea and its extract on biomarkers
of inﬂammation (e.g., ICAM-1, VCAM-1, IL-1β, IL-6, CRP, and
adiponectin) in obese patients with metabolic syndrome. After
8 weeks treatment, green tea did not change the biomarker levels
(Basu et al., 2011). Another clinical trial reported a useful impact
of topical EGCG treatment on acne vulgaris, which may be in part
due to anti-inﬂammatory eﬀects (Yoon et al., 2013). A green tea
extract was approved as a prescription drug in 2006 for the topical
treatment of anal and genital warts (Condylomata acuminate).
This key development fueled additional research to expand the
indications of EGCG. Sixty-eight clinical trials are listed on http://
www.clinicaltrials.gov/ for upcoming years. Fifteen studies are in
recruiting stage while 33 studies have been completed. EGCGwill
be tested for its eﬀects on albuminuria in diabetic nephropathy
along with its action in patients with multiple-system atrophy,
Huntington’s disease, fragile X syndrome, Down syndrome,
Alzheimer’s disease (early stage), muscular dystrophy of the
Duchenne type, and cardiac amyloid light-chain amyloidosis.
Furthermore, the trials will study the potential of EGCG on
preventing colon polyps in patients at high risk for recurrent
colon adenoma and on reactivation of the Epstein–Barr virus in
remission patients. More studies will investigate whether topical
EGCG exerts an anticarcinogenic potential in patients with
superﬁcial basal cell carcinoma, whether gargling with EGCG
inhibits inﬂuenza infections in teenagers and whether EGCG
aﬀects the resistance of insulin. Evidently, the trials will not study
classic inﬂammatory disorder, though some of the mentioned
diseases are linked with inﬂammatory processes (e.g., insulin
resistance or Alzheimer’s disease). Nonetheless, it is probable that
EGCG will experience an expansion of its indication in future.
Quercetin
The ﬂavonol, quercetin, chemically 2-(3,4-dihydroxyphenyl)-
3,5,7-trihydroxychromen-4-one, belongs to the family of
polyphenols representing very extensively spread secondary
plant metabolites. Quercetin is found in a variety of food
like tea, capers, red onions, broccoli, berries, grapevines, and
apples. Quercetin has been found to exert anti-mutagenic,
anti-oxidative, anti-inﬂammatory, anticancer/chemopreventive,
neuroprotective, antihypertensive, and blood glucose-lowering
activities (Middleton et al., 2000). Quercetin activated various
kinases which phosphorylated eukaryotic initiation factor 2, thus
inhibiting cell translation (Ito et al., 1999). The mechanisms
behind these actions are wide and have been characterized
extensively. Quercetin scavenged nitrogen and reactive oxygen
species (ROS), targets noticeable pro-inﬂammatory signaling
pathways including MAPK, NF-κB and STAT1, and inhibits
replication of many types of viruses and infectivity of target
cells (Boots et al., 2008). The activity of COX-2 and iNOS
was inhibited by quercitin by the suppression of AP-1, NF-κB
and STAT-1 signaling in cytokine- or LPS-induced HUVECs
and macrophages (Hamalainen et al., 2007). The expression
of pro-inﬂammatory cytokines in calcium ionophore- and
PMA-induced mast cells was attenuated by quercitin. Moreover,
the TNF-α-stimulated NF-κB recruitment to pro-inﬂammatory
gene promoters was also suppressed by quercitin in murine
intestinal epithelial cells (Ruiz et al., 2007; Park et al., 2008).
The TNF-α- or PMA-induced expression of ICAM-1 in human
endothelial cells was decreased by quercitin (Kobuchi et al.,
1999). The LPS-stimulated NF-κB and nitrite oxide production
was also inhibited by quercitin in mice.
A number of studies on inﬂammatory parameters in humans
have been performed in the past few years: one clinical trial
estimated the eﬀect of quercetin on biomarkers of inﬂammation
depending on the apo-lipoprotein E genotype of healthy men.
Though the risk factors of cardiovascular disease were improved,
quercetin exerted a slight pro-inﬂammatory eﬀect (Pfeuﬀer et al.,
2013). After repeated sprint exercise, quercetin did not aﬀect
the levels of the pro-inﬂammatory cytokine IL-6 (Abbey and
Rankin, 2011). Quercetin decreased the markers of inﬂammation
(IL-8 and TNF-α) in sarcoidosis patients (Boots et al., 2011).
Quercetin did not change phagocytosis activity, granulocyte
oxidative burst or blood leukocyte subsets, TNF-α or IL-6
plasma levels in healthy females (Heinz et al., 2010). It is worth
mentioning that no trial reports on the improvement of clinical
parameters of inﬂammatory diseases (incidence and severity).
Ten trials are registered on http://www.clinicaltrials.gov/ that will
use pure quercetin. Regarding inﬂammatory disorders, quercetin
will be analyzed in two-phase 1–2 trials for its dose-response
relationship and safety in chronic obstructive pulmonary disease.
For diabetes, quercetin will be tested in a phase 2 trial for its eﬀect
on blood vessel function and blood glucose in type 2 diabetes.
Quercetin will also be administered in obese patients (with or
without type 2 diabetes) to investigate its action on glucose
absorption. In study related to cancer, it will be studied whether
quercetin can prevent prostate cancer and whether it controls
levels of prostate-speciﬁc antigen. Additionally, quercetin will be
administered in childrenwith Fanconi anemia (pharmacokinetics
and safety). Therefore, quercetin will go through interesting
studies that may lead to insightful development of knowledge
regarding its clinical eﬃcacy. Though, inﬂammatory diseases are
not the main areas of current research.
Colchicine
The tropolone derivative, colchicine, chemically (N-[(7S)-1,2,
3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo(a)heptalen-7]
-ylacetamide), is the main alkaloid of Colchicum autumnale
(family: Colchicaceae), generally called meadow saﬀron
or autumn crocus. The extracts of this plant have been
used against gout attacks for centuries. The US FDA has
approved colchicine for the prevention and treatment of
familial mediterranean fever and acute gout ﬂares. To obtain
this approval, the applying company provided new clinical
data and was thus given an exclusive marketing agreement,
7 years for familial Mediterranean fever and 3 years for the
indication gout (orphan drug status). The mechanisms of action
of colchicine are extensively studied: the molecular target was
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recognized, the binding spot was accurately characterized, and
the biological consequences of damaging microtubule dynamics
were examined; complete reviews summarizing these results
are available (Bhattacharyya et al., 2008; Nuki, 2008; Stanton
et al., 2011). In 1960s, colchicine played a key role for the initial
characterization of tubulin subunits and microtubules (Borisy
and Taylor, 1967).
In spite of this vast knowledge, researchers have recently
conducted numerous trials to expand its ﬁelds of application.
Several trials in the ﬁeld of inﬂammation-associated pathologies
with positive outcome: colchicine was tested as an adjunct
treatment against acute pericarditis. In an open-label, single-
center randomized trial, colchicine addition to glucocorticoids
or aspirin traditional treatment reduced the reappearance
to half, after early occurrence of acute pericarditis. In a
placebo controlled, double-blind, randomized, multicenter trial,
colchicine, when added to traditional anti-inﬂammatory therapy,
substantially decreased the rate of recurrent or incessant
pericarditis (Imazio et al., 2005a,b, 2011, 2013), to prevent
atrial ﬁbrillation after radiofrequency ablation (Deftereos et al.,
2012) and for the prevention of post-pericardiotomy syndrome
(Imazio et al., 2010). These well-performed and large studies will
deﬁnitely aﬀect pharmacotherapy guidelines. And the ﬁeld is still
active: 19 clinical trials that are in the recruiting phase, are listed
on http://www.clinicaltrials.gov/. They aim to study the action of
colchicine primarily in the areas of nephrology and cardiology,
for instance, in myocardial infarction, for the prevention of post-
pericardiotomy syndrome, or in diabetic nephropathy-all related
to inﬂammatory processes. Colchicine will be investigated to
determine its eﬀects on metabolism in adults who are overweight
but have not yet developed diabetes. As the number of diseases
with an inﬂammatory component is large, one might wonder that
colchicine will further stay an interesting, not yet fully used drug.
Capsaicin
Capsaicin, chemically (E)-N-[(4-hydroxy-3-methoxyphenyl)
methyl]-8-methylnon-6-enamide, is a hydrophobic alkaloid
found in chili peppers (Capsicum species; Solanaceae) and
accounts for the characteristic spiciness/pungency of the fruits
of the genus. It has been used in traditional medicine as a
counter-irritant and topical rubefacient to relieve pain of joints
and muscles. Recently, an 8% capsaicin cutaneous patch has
been approved by the EU for use in non-diabetic adults against
neuropathic pain and in US against neuropathic pain linked with
post-herpetic neuralgia. The research on capsaicin resulted in
the discovery of transient receptor potential channel vanilloid
subfamily member 1 (TRPV1), which is the direct target of
capsaicin (Caterina et al., 1997). TRPV1 is a positively charged
indiscriminate channel mainly located in nociceptive neurons
with high preference for Ca2+. It is activated by physical and
chemical stimuli, like certain inﬂammatory mediators, capsaicin,
low pH and heat (O’Neill et al., 2012). Extended activation of
TRPV1 by capsaicin was found to cause desensitization and,
therefore, decreased pain sensation (Haanpaa and Treede,
2012). Apart from pain, numerous studies in arthritic rats also
discovered that capsaicin could inhibit paw inﬂammation (Joe
et al., 1997; Park et al., 2000) and ethanol-induced inﬂammation
of gastric mucosa in rats. Furthermore, capsaicin was found to
inhibit NF-κB pathway, iNOS expression and COX-2 activity
in the macrophages in a TRPV1-independent manner (Kim
et al., 2003). Regarding inﬂammation, capsaicin was studied in
a latest review by the Cochrane Collaboration: topical capsaicin
was discovered to be ineﬀective against osteoarthritis (Cameron
and Chrubasik, 2013). In comparison, one meta-analysis found
adequate evidence to report that capsaicin was eﬀective in the
management of osteoarthritis, though the authors reported
the lacking of randomized clinical trials (De Silva et al., 2011).
As far as future therapeutic enhancements are concerned, 24
clinical trials are currently recruiting or are planned, as listed
on http://www.clinicaltrials.gov/. Majority of these studies use
capsaicin as a model substance to induce pain or as a diagnostic
tool. Studies that examine the therapeutic potential of capsaicin
study its potential as pre-emptive analgesic in patients going
through amputation of a limb and its eﬀect on neuropathic
pain from critical ischemia (mainly in feet and hands) and on
chronic pain from artiﬁcial arteriovenous ﬁstulae in end-stage
renal failure patients. Besides, capsaicin will be tested against
the decreased swallow response in stroke patients with or
opharyngeal dysphagia and against persistent pain after inguinal
herniotomy. A study on the mechanism of action of capsaicin
against idiopathic rhinitis will be carried out. No study will
investigate the immunomodulatory eﬀects of capsaicin. It can
be concluded that, in comparison with neuropathic pain, the
ﬁeld of inﬂammation and capsaicin is not very cutting-edge and
will stay on that level in the near future owing to lack of clinical
trials.
Andrographolide
Andrographolide is a diterpenoid lactone found in Andrographis
paniculata. Chemically, it is (3-[2-[decahydro-6-hydroxy-5-
(hydroxymethyl)-5, 8-dimethyl-2-methylene-1-napthalenyl]
ethylidene] dihydro- 4-hydroxy-2(3H)-furanone). Diverse
biological activities have been exhibited by andrographolide.
Numerous immunomodulatory activities of andrographolide
have been observed in vitro including reduction of IL-12,
TNF-α, PGE2, NO, COX-2 and iNOS in microglia and
macrophages (Maiti et al., 2006). The LPS-stimulated iNOS
and COX-2 expression in RAW264.7 macrophages was
inhibited by andrographolide. It also inhibited Akt and Erk 1/2
signaling, consequently inhibiting the chemotactic migration of
macrophages on the site of inﬂammation (Tsai et al., 2004; Qin
et al., 2006). In neutrophils, the production of ROS was inhibited
by andrographolide (Shen et al., 2002). Andrographolide
regulated the production of factors such as NK cells, IFN-γ, IL-2,
and TNF-α. The administration of andrographolide resulted in
improved expression of CD markers and production of TNF-α,
therefore increasing the cytotoxic potential of lymphocytes
(Rajagopal et al., 2003). Andrographolide inhibited IL-2, IFNγ
and IL-6 expression, decreasing the cellular and humoral
adaptive immune reaction in T cells. Andrographolide decreased
the antigen-presenting potential of dendritic cells to T cells. In
an ovalbumin-induced asthma rat model, the andrographolide
administration decreased the serum immunoglobulin, IL-13,
IL-4, IL-5, and Th2 cytokine. Andrographolide decreased
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migration and invasion, endothelial cell proliferation and
adhesion molecule ICAM-1, signifying its role in angiogenesis
(Chiou et al., 2000). The functions of NF-κB were inhibited by a
number of immunomodulatory responses and andrographolide
inhibited NF-κB binding to DNA and hence decreasing pro-
inﬂammatory proteins expression like iNOS and COX-2 (Wang
et al., 2004; Xia et al., 2004; Hidalgo et al., 2005; Iruretagoyena
et al., 2005). Andrographolide down regulated COX-2 and iNOS
gene expression by inhibiting NF-κB and signal transducer and
activator of transcription-3 (STAT3) expression via suppressing
the expression of suppressor of cytokine signaling 1 and 3
(Lee et al., 2011). Zhang et al. (2014) conducted a study to
determine the eﬀect of andrographolide on insulinoma tumor
growth. Andrographolide was found to inhibit the progression
of insulinoma tumor by targeting the TLR4/NF-κB signaling
pathway (Zhang et al., 2014).
In spite of this vast knowledge, researchers have recently
conducted numerous trials to expand its ﬁelds of application.
But most of the trials have been conducted by using the crude
extract. A double blind study was conducted on 101 patients
with moderately active Crohn’s disease to assess the eﬃcacy and
safety of aqueous ethanol extract of A. paniculata. At week 8 of
treatment, a signiﬁcant decrease in the mean C-reactive protein
level was observed in extract treated group as compared with
the placebo group (Sandborn et al., 2010). A phase II study
in patients with mildly to moderately active ulcerative colitis
demonstrated that the eﬃcacy of the aqueous ethanol extract
of A. paniculata was similar to that of slow release mesalazine
(Tang et al., 2011). In contrast to the patients with mildly
to moderately active ulcerative colitis receiving placebo, those
treated with A. paniculata extract were more probable to attain
clinical response (Sandborn et al., 2013). In a double blind
against placebo controlled clinical trial, the standardized patented
A. paniculata extract’s (Paractin R© ) eﬀect was evaluated in chronic
rheumatoid arthritis patients. A signiﬁcant reduction in total
grade of tender joints, number of tender joints, total grade of
swollen joint, number of swollen joints was observed. Serological
parameters and rheumatoid factor (C4 and IgA) of disease
were found to be reduced (Burgos et al., 2009). Currently, ﬁve
diﬀerent studies related to the various actions of andrographolide
could be found on http://www.clinicaltrials.gov/. Two trials are
registered on http://www.clinicaltrials.gov/ that will use pure
andrographolide. A double blind, interventional, randomized,
and placebo controlled phase II trial will determine the
safety, acceptability, and eﬀectiveness of andrographolide in
active rheumatoid arthritis-aﬀected patients and eﬀects on the
immunological functions that eﬀect chronic inﬂammation will
also be determined. A study will be conducted to determine the
eﬃcacy of andrographolide in retarding the progression of brain
atrophy in patients with progressive forms of multiple sclerosis.
Besides, the eﬃcacy and safety of andrographolide will also be
evaluated for the treatment of colorectal cancer.
Genistein
Genistein, chemically 4,5,7-trihydroxyisoﬂavone, is a naturally
occurring phytoestrogen, present in soy and soy-derived items.
Genistein is a renowned tyrosine kinase inhibitor. In vitro,
genistein inhibited IL-1b/IFNγ-induced COX-2 and iNOS
expression and in addition to producing PGE2 and NO in
human islets that may prevent pathogenesis of diabetes and
improve insulin resistance (Corbett et al., 1996). Like other
topoisomerase inhibitors, genistein induced apoptosis (Mccabe
and Orrenius, 1993). Genistein strongly inhibited angiogenesis,
exerted inhibiting eﬀect on proliferating cells (Fotsis et al.,
1995). Genistein regulates vascular function and protects
from atherosclerosis (Si and Liu, 2007). The administration
of genistein in human brain microvascular endothelial cells
and HUVECs signiﬁcantly inhibited the expression of TNF-
α-induced cell adhesion molecule CD106 and CD62E, and
monocyte adhesion (Lee and Lee, 2008). Genistein also reduced
the interaction between endothelial cells and monocyte via
activation of PPARs that reduced monocyte adhesion in culture
cells and animals (Kim et al., 2004; Chacko et al., 2007).
The LPS-stimulated secretion of MCP-1 from macrophages
was inhibited by genistein that resulted in decreased migration
of monocyte in vitro (Nagarajan et al., 2008). Genistein
inhibited LPS-induced expression of nitro tyrosine protein
and iNOS in vascular tissue that inhibits vascular alterations
and hypotension in vivo (Bermejo et al., 2003). Genistein
exerted potential eﬀect on chronic colitis, neurodegenerative
diseases, rheumatoid arthritis, metabolic disorders, and diabetes
by modulating inﬂammatory response. For example, genistein
inhibited production of pro-inﬂammatory molecules called
as markers of cartilage catabolism (HC gp-39, IL-1b, and
NO) in LPS-induced human chondrocytes (Hooshmand et al.,
2007). Genistein modulated Th1-predominant immune response
by increasing IL-4 production and suppressing the secretion
of IFN-γ in a collagen-induced rheumatoid arthritis rat
(Wang et al., 2008). NAFLD is an obesity-linked fatty liver
illness sourced by pro-inﬂammatory cytokines and TNF-α
and results in increase fatty acid uptake and the dysfunction
of hepatocytes. Genistein reduced the high fat diet-induced
steatohepatitis by improving liver function and decreasing
plasma TNF-α level in rat (Yalniz et al., 2007). Moreover,
genistein reduced LPS-stimulated dopamine uptake loss in
rat mesencephalic neuron glial cells by decreasing production
of TNF-α and NO and microglia activation (Wang et al.,
2005) this might protect the pathogenesis of Parkinson’s
disease caused by dopaminergic neuron injury. The increase of
astrocytes at Ab deposition sites is the initial neuropathological
ﬂuctuation that starts inﬂammation in Alzheimer’s disease.
The production of Ab-stimulated inﬂammatory mediators IL-
1β, TNF-α, COX-2, and iNOS in astrocytes was decreased
by genistein treatment, probably by PPARs’ activation (Valles
et al., 2010). Likewise, oral administration of genistein decreased
TNBS-stimulated chronic colitis by inhibition of COX-2
mRNA and protein expression together with the colonic
myeloperoxidase (MPO) activity in rat that applies useful anti-
inﬂammatory eﬀects in the treatment of IBD (Seibel et al.,
2009).
Genistein has undergone clinical trials for a variety of diseases
like type 2 diabetes mellitus, menopause, osteopenia, and various
types of cancer. The most noticeable diseases for which trails
had been conducted were cancer. Genistein is undergoing clinical
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trials for chemopreventive and chemotherapeutic purposes
in various cancers. Currently 11 open clinical trials have
been in recruiting or planned according to http://www.
clinicaltrials.gov. The main ﬁeld of interest is cancer (colon
cancer; rectal cancer; colorectal cancer, prostate cancer, bladder
cancer, adenocarcinoma, pancreatic adenocarcinoma) followed
by osteoporosis, hypercholesterolemia, Alzheimer’s disease and
menopause.
Conclusions and Future Prospects
Natural products and folklore medicines are the main
contributors of the leads in the design and development of
therapeutic agents. Several plant derived compounds have
been identiﬁed over the years for their immunomodulatory
characteristics. Numerous illnesses can be alternatively treated
by immunomodulation using medicinal plants, instead of
chemotherapy. The discovery and isolation of more speciﬁc
immunomodulatory agents from plant origin possesses potential
to counteract the side eﬀects and high cost of synthetic
compounds. This review highlights the signiﬁcance of medicinal
plants as producers of immunomodulatory molecules of very
varied chemistries with possible uses in animal and human
health. The challenges encountered by the application of plant-
derived immunomodulators need to be addressed. Though,
the path from traditional medicines to western pharmaceutical
practices is not always easy. The inconsistency of responses
of phytomedical practices can be clariﬁed in terms of the
typically strong reliance of plant secondary metabolite proﬁles
on environmental signals that can disturb reproducibility of
results with extracts. This can be decreased if the principles of
standardization of extracts and enriched fractions are thoroughly
applied.
In most of studies conducted to determine the eﬀect on
immune system, no adequate microbial contamination control
protocols were applied. Researchers report that the microbial
endotoxin can change the parameters of immune system.
Therefore, appropriate precautions must be taken to counter the
microbial contamination. An additional task is the classiﬁcation
of plant-derived immunomodulatory agents in a speciﬁc class
or among classes as per inherent risk. This classiﬁcation of
novel plant derived immunomodulatory agents by level of risk
can be endeavored from collective knowledge of meta-analyses
of clinical trials, national registries and physicians. Another
signiﬁcant constraint with natural products is inadequate
quantities, needed for development and clinical use. So, the
development of novel isolation techniques to improve the
amount for pharmaceutical applications needs more attention
of researchers. A major clinical restraint of these substances
is the low bioavailability. Nanotechnology and other delivery
strategies are being applied to enhance their eﬃcacy when
administered to humans. Lastly, there is a deﬁciency of standard
checking and quality control procedures to assure the eﬃcacy and
quality of the plant derived medicinal products for prospective
pharmaceutical applications. A few plant derived compounds,
including polysaccharides, are extremely diversiﬁed in terms
of molecular weight and structure; therefore, it is challenging
to produce the similar quality in every batch. Accumulative
requirement for these plant-derived products would motivate
improvement to overwhelming these obstacles for reaching
market.
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